Treatment And Prognosis Of Cirrhotic Esophagogastric Varices Bleeding

Objective:By comparing drug therapy,endoscopic treatment,and jugular intrahepatic portosystemic shunt therapy(TIPS),the clinical efficacy and prognosis of cirrhotic esophagogastric varices bleeding provide a scientific reference for clinical diagnosis and treatment.Methods:Retrospective analysis of 80 patients with upper gastrointestinal hemorrhage admitted to the Department of Gastroenterology,Ningbo Cangzhou People’s Hospital from June 2015 to June 2016.The relevant medical history,imaging examination and endoscopic findings confirmed cirrhosis of esophagogastric varices According to different treatment options,80 patients were divided into three groups: drug treatment(27 cases),endoscopic treatment(45 cases)and jugular intrahepatic portosystem(8 cases),statistical analysis Compare the general information(including age,gender,etiology,etc.)between the patients,pay attention to the changes of blood routine and blood biochemistry(including platelet,liver and kidney function,etc.)and coagulation function before and after treatment,and compare the number of rebleeding after treatment.,the rate of re-bleeding,the level of survival.These indicators were subjected to single factor statistics and analyzed using statistical software.In this study,SPSS 23.0 statistical software was used to screen out the statistically significant differences(P < 0.05),and to evaluate the efficacy and safety of the treatment of esophageal varices bleeding.Results:There were no significant differences in total bilirubin,alanine aminotransferase,prothrombin time,and albumin between the three groups before and after treatment.(P<0.05).At 6 months and 1 year after treatment,the platelet index of patients in TIPS group was significantly higher than that before treatment,but there was no significant difference(P>0.05).At 3 months,6 months,and 1 year after treatment,the rebleeding rate of the two groups in the TIPS group and the endoscopy group was significantly lower than that in the drug group(P<0.05).One year after treatment,there was no significant difference in mortality between the endoscopic group and the TIPS group(6.67%,12.5%)(P>0.05),but they were far lower than the drug group(25.9%).Academic significance(P <0.05).In patients with different Child classification,patients with grade C were significantly higher in rebleeding rate and mortality than those in grade A and grade B,with statistical differences.Conclusions:(1)Compared with the three groups,there was no significant difference in total bilirubin,alanine aminotransferase,prothrombin time,and albumin before and after treatment.(2)At 6 months and 1 year after treatment,platelets in the TIPS group increased significantly compared with those before treatment,and there were statistical differences.(3)The rebleeding rate of patients in TIPS group and endoscopy group was significantly lower than that in drug group at 3 months,6 months and 1 year after treatment,and there was statistical difference.(4)One year after treatment,there was no significant difference in mortality(6.67%,12.5%)between the endoscopic group and the TIPS group,but they were far lower than those in the drug group(25.9%)..(5)One year after treatment,Child C patients were significantly higher in rebleeding rate and mortality than those in Grade A and B patients,with statistical differences.